{ "run": { "id": "cmnr148ly04egp658l1eow5pn", "region": "US", "assetId": "cmnr148lg04ecp658eq9gzl47", "ticker": "IFF", "snapshotId": "cmnr148lo04eep658rqgidb2y", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:21:07.987Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr148lo04eep658rqgidb2y", "assetId": "cmnr148lg04ecp658eq9gzl47", "asOf": "2026-04-08T20:00:02.000Z", "snapshot": { "asOf": "2026-04-08T20:00:02.000Z", "quote": { "asOf": "2026-04-08T20:00:02.000Z", "open": null, "price": 73.77, "dayLow": 71.77, "volume": 2093355, "dayHigh": 74.05, "currency": "USD", "prevClose": 69.98, "week52Low": 59.14, "week52High": 84.45 }, "fundamentals": { "pe": -47.7943262411348, "beta": 0.858827326262862, "epsTTM": -1.41, "fcfTTM": -402000000, "growth": { "epsYoy": -2.48421052631579, "revenueYoy": -0.05172413793103448 }, "sector": "Industrial Organic Chemicals", "margins": { "net": -0.03296602387511478, "gross": 0.3616161616161616, "operating": -0.03507805325987144 }, "website": "https://iff.com/", "industry": "Specialty chemicals", "pegRatio": 0.19239241495372, "ebitdaTTM": 1161000000, "forwardPe": 15.109865470852, "marketCap": 18848336277, "totalCash": 590000000, "totalDebt": 6891000000, "debtEquity": 0.486858838490886, "quickRatio": 0.590134757182812, "revenueTTM": 10890000000, "companyName": "INTERNATIONAL FLAVORS & FRAGRANCES INC", "priceToBook": 1.21611729874524, "currentRatio": 1.42232392575642, "dividendYield": 0.0237076161151506, "returnOnAssets": -0.014056932534555, "returnOnEquity": -0.0253638547407093, "analystOpinions": null, "businessSummary": "International Flavors & Fragrances Inc. (IFF) is an American corporation that creates products across taste, texture, scent, nutrition, enzymes, cultures, soy proteins, and probiotics categories, which it markets globally. It is headquartered in New York City and has creative, sales, and manufacturing facilities in 44 countries. The company is a member of the S&P 500 index.", "enterpriseValue": 23552840000, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 22400, "sharesOutstanding": 255477487, "enterpriseToEbitda": 20.28668389319552, "analystTargetMedian": null, "enterpriseToRevenue": 2.162795224977043, "operatingCashflowTTM": 850000000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:21:07.981Z" }, "results": [ { "id": "cmnr148m104eip658zi1mub1w", "runId": "cmnr148ly04egp658l1eow5pn", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"claude-sonnet-4-20250514\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"IFF\",\"currency\":\"USD\",\"current_price\":73.77,\"target_price_6m\":76.0,\"target_price_12m\":78.0,\"recommendation\":\"HOLD\",\"confidence\":0.48,\"thesis_bullets\":[\"Negative TTM EPS and FCF signal ongoing operational stress post-merger integration\",\"Forward PE of 15.1x implies market expects meaningful earnings recovery ahead\",\"High leverage at $6.9B total debt constrains financial flexibility and shareholder returns\",\"Revenue declining 5.2% YoY amid weak demand in specialty chemicals end-markets\",\"Dividend yield of 2.4% provides modest income but payout sustainability uncertain\"],\"key_drivers\":[{\"driver\":\"Earnings recovery trajectory from negative TTM EPS to ~$4.88 forward EPS\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Debt reduction through potential divestitures and cash generation improvement\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Revenue decline of 5.2% YoY reflecting soft end-market demand\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Negative free cash flow of -$402M limits strategic flexibility\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"EBITDA of $1.16B provides cash flow cushion despite GAAP losses\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Gross margin at 36.2% shows underlying business quality\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"EV/EBITDA at 20.3x is elevated for specialty chemicals sector\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Portfolio rationalization and restructuring costs depressing near-term profitability\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Low PEG ratio of 0.19 suggests growth rebound is underpriced if delivered\",\"impact\":\"LOW\",\"direction\":\"POS\"}],\"risks\":[\"Earnings recovery fails to materialize, prolonging negative EPS and FCF period\",\"Debt refinancing risk as $6.9B debt matures in rising rate environment\",\"Further revenue deterioration in key segments erodes EBITDA base\",\"Divestiture proceeds disappoint or execution delays capital allocation plans\",\"Dividend cut risk if FCF remains negative, triggering further equity derating\",\"Integration of DuPont N&B continues to generate unexpected costs or dissynergies\"],\"assumptions\":{\"revenue_cagr_3y\":0.025,\"ebit_margin_target\":0.13,\"wacc\":0.09,\"terminal_multiple\":14.0},\"scenarios\":{\"bear\":{\"target_price\":60.0,\"prob\":0.25,\"notes\":\"Revenue stagnation, EBITDA declines, multiple compresses to 15x EV/EBITDA on $1.0B EBITDA.\"},\"base\":{\"target_price\":78.0,\"prob\":0.50,\"notes\":\"Gradual earnings recovery to ~$4.50 EPS, modest revenue growth, debt reduction via divestitures.\"},\"bull\":{\"target_price\":95.0,\"prob\":0.25,\"notes\":\"Full earnings recovery to $5.50+ EPS, margin expansion, accelerated deleveraging boosts equity value.\"}},\"method_notes\":\"Blended valuation using forward PE (15-17x on recovering EPS) and EV/EBITDA (14-16x on normalized EBITDA of $1.4-1.6B). Current negative EPS/FCF creates high uncertainty. Forward PE of 15.1 implies ~$4.88 EPS which at 16x gives ~$78. High debt ($6.9B) and negative FCF weigh on near-term upside. HOLD reflects modest expected return (~5.7%) combined with elevated uncertainty from ongoing losses and leverage. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "claude-sonnet-4-20250514", "risks": [ "Earnings recovery fails to materialize, prolonging negative EPS and FCF period", "Debt refinancing risk as $6.9B debt matures in rising rate environment", "Further revenue deterioration in key segments erodes EBITDA base", "Divestiture proceeds disappoint or execution delays capital allocation plans", "Dividend cut risk if FCF remains negative, triggering further equity derating", "Integration of DuPont N&B continues to generate unexpected costs or dissynergies" ], "ticker": "IFF", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Gradual earnings recovery to ~$4.50 EPS, modest revenue growth, debt reduction via divestitures.", "target_price": 78 }, "bear": { "prob": 0.25, "notes": "Revenue stagnation, EBITDA declines, multiple compresses to 15x EV/EBITDA on $1.0B EBITDA.", "target_price": 60 }, "bull": { "prob": 0.25, "notes": "Full earnings recovery to $5.50+ EPS, margin expansion, accelerated deleveraging boosts equity value.", "target_price": 95 } }, "confidence": 0.48, "assumptions": { "wacc": 0.09, "revenue_cagr_3y": 0.025, "terminal_multiple": 14, "ebit_margin_target": 0.13 }, "key_drivers": [ { "driver": "Earnings recovery trajectory from negative TTM EPS to ~$4.88 forward EPS", "impact": "HIGH", "direction": "POS" }, { "driver": "Debt reduction through potential divestitures and cash generation improvement", "impact": "HIGH", "direction": "POS" }, { "driver": "Revenue decline of 5.2% YoY reflecting soft end-market demand", "impact": "HIGH", "direction": "NEG" }, { "driver": "Negative free cash flow of -$402M limits strategic flexibility", "impact": "HIGH", "direction": "NEG" }, { "driver": "EBITDA of $1.16B provides cash flow cushion despite GAAP losses", "impact": "MED", "direction": "POS" }, { "driver": "Gross margin at 36.2% shows underlying business quality", "impact": "MED", "direction": "POS" }, { "driver": "EV/EBITDA at 20.3x is elevated for specialty chemicals sector", "impact": "MED", "direction": "NEG" }, { "driver": "Portfolio rationalization and restructuring costs depressing near-term profitability", "impact": "MED", "direction": "NEG" }, { "driver": "Low PEG ratio of 0.19 suggests growth rebound is underpriced if delivered", "impact": "LOW", "direction": "POS" } ], "method_notes": "Blended valuation using forward PE (15-17x on recovering EPS) and EV/EBITDA (14-16x on normalized EBITDA of $1.4-1.6B). Current negative EPS/FCF creates high uncertainty. Forward PE of 15.1 implies ~$4.88 EPS which at 16x gives ~$78. High debt ($6.9B) and negative FCF weigh on near-term upside. HOLD reflects modest expected return (~5.7%) combined with elevated uncertainty from ongoing losses and leverage. Not investment advice.", "current_price": 73.77, "recommendation": "HOLD", "thesis_bullets": [ "Negative TTM EPS and FCF signal ongoing operational stress post-merger integration", "Forward PE of 15.1x implies market expects meaningful earnings recovery ahead", "High leverage at $6.9B total debt constrains financial flexibility and shareholder returns", "Revenue declining 5.2% YoY amid weak demand in specialty chemicals end-markets", "Dividend yield of 2.4% provides modest income but payout sustainability uncertain" ], "target_price_6m": 76, "target_price_12m": 78 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 52878, "createdAt": "2026-04-09T05:21:07.987Z", "usage": { "inputTokens": 3609, "outputTokens": 2479, "costUsd": 0.08002 } }, { "id": "cmnr148m104elp658b3r5p2k9", "runId": "cmnr148ly04egp658l1eow5pn", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"Equity Research AI Model\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"IFF\",\n \"currency\": \"USD\",\n \"current_price\": 73.77,\n \"target_price_6m\": 65.0,\n \"target_price_12m\": 59.6,\n \"recommendation\": \"SELL\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"High EV/EBITDA multiple suggests overvaluation.\",\n \"Declining revenue and negative EPS indicate challenges.\",\n \"Forward P/E implies recovery but may be optimistic.\",\n \"Negative free cash flow pressures financial flexibility.\",\n \"Industry headwinds could further erode margins.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"EBITDA margin improvement\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Revenue growth stabilization\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"EV/EBITDA multiple contraction\", \"impact\": \"HIGH\", \"direction\": \"NEG\" },\n { \"driver\": \"Cost reduction initiatives\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Raw material price volatility\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Competitive pressures in market\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Debt servicing costs\", \"impact\": \"LOW\", \"direction\": \"NEG\" },\n { \"driver\": \"Product innovation success\", \"impact\": \"MED\", \"direction\": \"POS\" }\n ],\n \"risks\": [\n \"Further decline in consumer demand.\",\n \"Failure to improve operating margins.\",\n \"Rising interest rates increasing costs.\",\n \"Execution risks in turnaround strategy.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.02,\n \"ebit_margin_target\": 0.08,\n \"wacc\": 0.085,\n \"terminal_multiple\": 16.0\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 50.0, \"prob\": 0.2, \"notes\": \"Severe margin pressure and higher multiple contraction.\" },\n \"base\": { \"target_price\": 59.6, \"prob\": 0.6, \"notes\": \"Moderate EBITDA growth and multiple contraction to 18x.\" },\n \"bull\": { \"target_price\": 70.0, \"prob\": 0.2, \"notes\": \"Faster recovery and sustained higher valuation multiples.\" }\n },\n \"method_notes\": \"Valuation based on EV/EBITDA analysis with sensitivity scenarios. SELL due to high current multiple vs. declining fundamentals. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "Equity Research AI Model", "risks": [ "Further decline in consumer demand.", "Failure to improve operating margins.", "Rising interest rates increasing costs.", "Execution risks in turnaround strategy." ], "ticker": "IFF", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Moderate EBITDA growth and multiple contraction to 18x.", "target_price": 59.6 }, "bear": { "prob": 0.2, "notes": "Severe margin pressure and higher multiple contraction.", "target_price": 50 }, "bull": { "prob": 0.2, "notes": "Faster recovery and sustained higher valuation multiples.", "target_price": 70 } }, "confidence": 0.65, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.02, "terminal_multiple": 16, "ebit_margin_target": 0.08 }, "key_drivers": [ { "driver": "EBITDA margin improvement", "impact": "HIGH", "direction": "POS" }, { "driver": "Revenue growth stabilization", "impact": "HIGH", "direction": "POS" }, { "driver": "EV/EBITDA multiple contraction", "impact": "HIGH", "direction": "NEG" }, { "driver": "Cost reduction initiatives", "impact": "MED", "direction": "POS" }, { "driver": "Raw material price volatility", "impact": "MED", "direction": "NEG" }, { "driver": "Competitive pressures in market", "impact": "MED", "direction": "NEG" }, { "driver": "Debt servicing costs", "impact": "LOW", "direction": "NEG" }, { "driver": "Product innovation success", "impact": "MED", "direction": "POS" } ], "method_notes": "Valuation based on EV/EBITDA analysis with sensitivity scenarios. SELL due to high current multiple vs. declining fundamentals. Not investment advice.", "current_price": 73.77, "recommendation": "SELL", "thesis_bullets": [ "High EV/EBITDA multiple suggests overvaluation.", "Declining revenue and negative EPS indicate challenges.", "Forward P/E implies recovery but may be optimistic.", "Negative free cash flow pressures financial flexibility.", "Industry headwinds could further erode margins." ], "target_price_6m": 65, "target_price_12m": 59.6 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 337, "createdAt": "2026-04-09T05:21:07.987Z", "usage": { "inputTokens": 2116, "outputTokens": 3219, "costUsd": 0.001944 } }, { "id": "cmnr148m104ejp658q4stgrep", "runId": "cmnr148ly04egp658l1eow5pn", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"Equity Research Valuation Model\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"IFF\",\n \"currency\": \"USD\",\n \"current_price\": 73.77,\n \"target_price_6m\": 78.50,\n \"target_price_12m\": 84.00,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.68,\n \"thesis_bullets\": [\n \"Strategic divestitures of non-core assets are effectively accelerating the deleveraging process.\",\n \"Volume recovery in Scent and Taste segments as customer destocking cycles conclude.\",\n \"Operational efficiency initiatives are projected to drive meaningful EBITDA margin expansion.\",\n \"Valuation discount to historical averages and peers provides a favorable entry point.\",\n \"Stabilizing input costs and pricing power support gross margin recovery through 2026.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Consumer staples volume recovery\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Debt reduction from asset sales\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Raw material cost stabilization\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Restructuring execution efficiency\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Global interest rate environment\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Competitive pricing in ingredients\",\n \"impact\": \"LOW\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Execution risk associated with complex business unit divestitures.\",\n \"Potential for prolonged weakness in discretionary consumer spending.\",\n \"High leverage levels relative to peers during economic volatility.\",\n \"Currency fluctuations impacting international revenue translation.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.035,\n \"ebit_margin_target\": 0.145,\n \"wacc\": 0.082,\n \"terminal_multiple\": 13.5\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 61.00,\n \"prob\": 0.20,\n \"notes\": \"Stagnant volume growth and failure to meet deleveraging targets.\"\n },\n \"base\": {\n \"target_price\": 84.00,\n \"prob\": 0.55,\n \"notes\": \"Successful execution of cost-cutting and moderate organic growth.\"\n },\n \"bull\": {\n \"target_price\": 102.00,\n \"prob\": 0.25,\n \"notes\": \"Rapid margin expansion and significant valuation multiple re-rating.\"\n }\n },\n \"method_notes\": \"Valuation derived from a blend of 12-month forward EV/EBITDA (13.0x) and a 10-year DCF. Recommendation reflects a ~14% expected total return as the company transitions from restructuring to a leaner growth profile. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "Equity Research Valuation Model", "risks": [ "Execution risk associated with complex business unit divestitures.", "Potential for prolonged weakness in discretionary consumer spending.", "High leverage levels relative to peers during economic volatility.", "Currency fluctuations impacting international revenue translation." ], "ticker": "IFF", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Successful execution of cost-cutting and moderate organic growth.", "target_price": 84 }, "bear": { "prob": 0.2, "notes": "Stagnant volume growth and failure to meet deleveraging targets.", "target_price": 61 }, "bull": { "prob": 0.25, "notes": "Rapid margin expansion and significant valuation multiple re-rating.", "target_price": 102 } }, "confidence": 0.68, "assumptions": { "wacc": 0.082, "revenue_cagr_3y": 0.035, "terminal_multiple": 13.5, "ebit_margin_target": 0.145 }, "key_drivers": [ { "driver": "Consumer staples volume recovery", "impact": "HIGH", "direction": "POS" }, { "driver": "Debt reduction from asset sales", "impact": "HIGH", "direction": "POS" }, { "driver": "Raw material cost stabilization", "impact": "MED", "direction": "POS" }, { "driver": "Restructuring execution efficiency", "impact": "MED", "direction": "POS" }, { "driver": "Global interest rate environment", "impact": "MED", "direction": "NEG" }, { "driver": "Competitive pricing in ingredients", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Valuation derived from a blend of 12-month forward EV/EBITDA (13.0x) and a 10-year DCF. Recommendation reflects a ~14% expected total return as the company transitions from restructuring to a leaner growth profile. Not investment advice.", "current_price": 73.77, "recommendation": "BUY", "thesis_bullets": [ "Strategic divestitures of non-core assets are effectively accelerating the deleveraging process.", "Volume recovery in Scent and Taste segments as customer destocking cycles conclude.", "Operational efficiency initiatives are projected to drive meaningful EBITDA margin expansion.", "Valuation discount to historical averages and peers provides a favorable entry point.", "Stabilizing input costs and pricing power support gross margin recovery through 2026." ], "target_price_6m": 78.5, "target_price_12m": 84 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-flash-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 11708, "createdAt": "2026-04-09T05:21:07.987Z", "usage": { "inputTokens": 2472, "outputTokens": 808, "costUsd": 0.01464 } }, { "id": "cmnr148m104ehp658zc7uwx0h", "runId": "cmnr148ly04egp658l1eow5pn", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"OpenAI o3\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"IFF\",\"currency\":\"USD\",\"current_price\":73.77,\"target_price_6m\":76,\"target_price_12m\":78,\"recommendation\":\"HOLD\",\"confidence\":0.61,\"thesis_bullets\":[\"Recovery potential exists as volumes normalize and cost actions lift margins.\",\"Leverage remains elevated, limiting flexibility despite manageable liquidity.\",\"Negative TTM FCF and earnings keep valuation support dependent on execution.\",\"At ~15x forward P/E, shares look near fair versus recovery uncertainty.\",\"Dividend yield offers carry, but not enough to offset weak fundamentals alone.\"],\"key_drivers\":[{\"driver\":\"Volume stabilization in scent and taste\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Productivity and restructuring savings\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Cash conversion improvement\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Portfolio simplification/divestitures\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Deleveraging and lower interest burden\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Weak industrial and consumer demand\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Raw material and energy inflation\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"FX translation headwinds\",\"impact\":\"LOW\",\"direction\":\"NEG\"}],\"risks\":[\"Demand softness persists longer than expected.\",\"Margin recovery and restructuring benefits underdeliver.\",\"Leverage reduction stalls if free cash flow stays weak.\",\"Input-cost inflation or FX pressure compresses profits.\",\"Further impairments or regulatory issues hit sentiment.\"],\"assumptions\":{\"revenue_cagr_3y\":3.5,\"ebit_margin_target\":10.5,\"wacc\":8.7,\"terminal_multiple\":16},\"scenarios\":{\"bear\":{\"target_price\":63,\"prob\":0.25,\"notes\":\"Demand stays soft and cash conversion disappoints.\"},\"base\":{\"target_price\":78,\"prob\":0.5,\"notes\":\"Volumes stabilize and margins recover gradually.\"},\"bull\":{\"target_price\":90,\"prob\":0.25,\"notes\":\"Execution improves faster, supporting stronger deleveraging.\"}},\"method_notes\":\"Target uses a blended normalized earnings/EV framework from snapshot data: modest sales recovery, EBIT margin rebuilding, and a 16.0x terminal earnings anchor, tempered by leverage and negative TTM FCF. Snapshot quote fields were not overridden; no sell-side targets used; not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "OpenAI o3", "risks": [ "Demand softness persists longer than expected.", "Margin recovery and restructuring benefits underdeliver.", "Leverage reduction stalls if free cash flow stays weak.", "Input-cost inflation or FX pressure compresses profits.", "Further impairments or regulatory issues hit sentiment." ], "ticker": "IFF", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Volumes stabilize and margins recover gradually.", "target_price": 78 }, "bear": { "prob": 0.25, "notes": "Demand stays soft and cash conversion disappoints.", "target_price": 63 }, "bull": { "prob": 0.25, "notes": "Execution improves faster, supporting stronger deleveraging.", "target_price": 90 } }, "confidence": 0.61, "assumptions": { "wacc": 8.7, "revenue_cagr_3y": 3.5, "terminal_multiple": 16, "ebit_margin_target": 10.5 }, "key_drivers": [ { "driver": "Volume stabilization in scent and taste", "impact": "HIGH", "direction": "POS" }, { "driver": "Productivity and restructuring savings", "impact": "HIGH", "direction": "POS" }, { "driver": "Cash conversion improvement", "impact": "HIGH", "direction": "POS" }, { "driver": "Portfolio simplification/divestitures", "impact": "MED", "direction": "POS" }, { "driver": "Deleveraging and lower interest burden", "impact": "MED", "direction": "POS" }, { "driver": "Weak industrial and consumer demand", "impact": "HIGH", "direction": "NEG" }, { "driver": "Raw material and energy inflation", "impact": "MED", "direction": "NEG" }, { "driver": "FX translation headwinds", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Target uses a blended normalized earnings/EV framework from snapshot data: modest sales recovery, EBIT margin rebuilding, and a 16.0x terminal earnings anchor, tempered by leverage and negative TTM FCF. Snapshot quote fields were not overridden; no sell-side targets used; not investment advice.", "current_price": 73.77, "recommendation": "HOLD", "thesis_bullets": [ "Recovery potential exists as volumes normalize and cost actions lift margins.", "Leverage remains elevated, limiting flexibility despite manageable liquidity.", "Negative TTM FCF and earnings keep valuation support dependent on execution.", "At ~15x forward P/E, shares look near fair versus recovery uncertainty.", "Dividend yield offers carry, but not enough to offset weak fundamentals alone." ], "target_price_6m": 76, "target_price_12m": 78 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_0cda1c9228cf87bf0069d75a11fc288190ac604e1bba28d9db", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 59802, "createdAt": "2026-04-09T05:21:07.987Z", "usage": { "inputTokens": 2386, "outputTokens": 2940, "costUsd": 0.045336 } }, { "id": "cmnr148m104ekp658xdlvln8s", "runId": "cmnr148ly04egp658l1eow5pn", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research Model\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"IFF\",\n \"currency\": \"USD\",\n \"current_price\": 73.77,\n \"target_price_6m\": 79.0,\n \"target_price_12m\": 85.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.61,\n \"thesis_bullets\": [\n \"Portfolio strength supports pricing power and stability.\",\n \"Margin recovery programs targeting 12% EBIT by 2028.\",\n \"Innovation in nutrition segment fuels long-term demand.\",\n \"High debt and negative FCF constrain near-term flexibility.\",\n \"Forward valuation attractive if stabilization continues.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"EBIT margin expansion\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Revenue stabilization\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Innovation pipeline\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Debt reduction\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Input cost volatility\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Consumer spending slowdown\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Acquisition synergies\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Competition intensity\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Negative FCF persists longer than expected\",\n \"High debt burden raises interest costs\",\n \"Commodity inflation erodes margins\",\n \"Regulatory shifts in food ingredients\",\n \"Demand weakness in key end markets\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.04,\n \"ebit_margin_target\": 0.12,\n \"wacc\": 0.085,\n \"terminal_multiple\": 16\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 62,\n \"prob\": 0.3,\n \"notes\": \"Margins stay compressed on cost pressures.\"\n },\n \"base\": {\n \"target_price\": 85,\n \"prob\": 0.5,\n \"notes\": \"Gradual recovery in volumes and margins.\"\n },\n \"bull\": {\n \"target_price\": 105,\n \"prob\": 0.2,\n \"notes\": \"Accelerated growth from innovation wins.\"\n }\n },\n \"method_notes\": \"3-stage DCF using rev CAGR, EBIT target, WACC and terminal EV/EBIT multiple plus peer context. 15% expected 12M return supports BUY. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI Equity Research Model", "risks": [ "Negative FCF persists longer than expected", "High debt burden raises interest costs", "Commodity inflation erodes margins", "Regulatory shifts in food ingredients", "Demand weakness in key end markets" ], "ticker": "IFF", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Gradual recovery in volumes and margins.", "target_price": 85 }, "bear": { "prob": 0.3, "notes": "Margins stay compressed on cost pressures.", "target_price": 62 }, "bull": { "prob": 0.2, "notes": "Accelerated growth from innovation wins.", "target_price": 105 } }, "confidence": 0.61, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.04, "terminal_multiple": 16, "ebit_margin_target": 0.12 }, "key_drivers": [ { "driver": "EBIT margin expansion", "impact": "HIGH", "direction": "POS" }, { "driver": "Revenue stabilization", "impact": "MED", "direction": "POS" }, { "driver": "Innovation pipeline", "impact": "MED", "direction": "POS" }, { "driver": "Debt reduction", "impact": "HIGH", "direction": "POS" }, { "driver": "Input cost volatility", "impact": "MED", "direction": "NEG" }, { "driver": "Consumer spending slowdown", "impact": "HIGH", "direction": "NEG" }, { "driver": "Acquisition synergies", "impact": "MED", "direction": "POS" }, { "driver": "Competition intensity", "impact": "MED", "direction": "NEG" } ], "method_notes": "3-stage DCF using rev CAGR, EBIT target, WACC and terminal EV/EBIT multiple plus peer context. 15% expected 12M return supports BUY. Not investment advice.", "current_price": 73.77, "recommendation": "BUY", "thesis_bullets": [ "Portfolio strength supports pricing power and stability.", "Margin recovery programs targeting 12% EBIT by 2028.", "Innovation in nutrition segment fuels long-term demand.", "High debt and negative FCF constrain near-term flexibility.", "Forward valuation attractive if stabilization continues." ], "target_price_6m": 79, "target_price_12m": 85 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "e1a3105d-9ece-9700-867b-5c9764dd8348", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 18522, "createdAt": "2026-04-09T05:21:07.987Z", "usage": { "inputTokens": 2726, "outputTokens": 3265, "costUsd": 0.057153 } } ] } }